Hopstem Wins the Third Prize of VB-Link Competition
Huayi List: Hopstem Ranks Top 10 Most Promising Biotech Companies
The iPSC-derived Human Forebrain Neural Progenitor Cell Injection hNPC01 of Hopstem has Received CDE's Clinical Implication Approval
The launch meeting of the clinical research project of Hopstem hNPC01 universal cell therapy product for the treatment of stroke sequelae was successfully held.
Good news! Hopstem has been awarded as one of the "Top 10 Organoid Enterprises with the Most Investment Value"!
Hopstem has honored to list on the “2023 Top 100 Future Healthcare List”
Hopstem won the "2022 Drug Innovation CHIP Seed TOP 10"
Hopstem was included in the list of 2022 Hangzhou Quasi-Unicorn Enterprises
R&D Center: 3rd Floor, Building 16, No.260 6th Street,
Economic and Technological Development Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,
Hexiang Technology Center, Qiantang New Area,
Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
